Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 6/2018

MODERN ORAL ANTICOAGULANT TREATMENT IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE: INSIGHTS FROM THE CLINICAL PRACTICE

OTILIA ANCA ȚICA 1,2#, OVIDIU ȚICA 2,3#*, LIANA ANTAL 2#, ADRIAN HATOS 4#, MIRCEA IOACHIM POPESCU 1,2#, ANCA PANTEA STOIAN 5#, OVIDIU GABRIEL BRATU 5,6#, MIHNEA-ALEXANDRU GĂMAN 5#, SILVIU MIREL PIȚURU 5#, CAMELIA CRISTINA DIACONU 5,7#

1.Emergency County Clinical Hospital of Oradea, Cardiology Clinic, Gheorghe Doja Street, no. 65, Oradea, Romania
2.Faculty of Medicine and Pharmacy, University of Oradea, 1st of December Square, no 10, Oradea, Romania
3.Emergency County Clinical Hospital of Oradea, Pathology Department, Gheorghe Doja Street, no. 65, Oradea, Romania
4.Faculty of Sociological Sciences, University of Oradea, Romanian Army Street no 5, Oradea, Romania
5.University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania
6.Emergency University Central Military Hospital, Bucharest, Romania
7.Clinical Emergency Hospital of Bucharest, Internal Medicine Clinic, Bucharest, Romania

Download Full Article PDF

Atrial fibrillation (AF) and heart failure (HF) are some of the most common cardiovascular pathologies of our century. These two pathologies can frequently coexist, raising particular diagnostic and therapeutic problems. Patients with AF and HF have a high thromboembolic risk, which justifies the indication of long-term anticoagulant therapy. Vitamin K antagonists (acenocoumarol) have long been the only oral therapeutic option for the prevention of embolic events in this category of patients. However, the great variability of their anticoagulant effect, with the necessity of monthly monitoring of the coagulation parameters, led to the search of newer therapeutic options, with a more predictable effect and reduced side effects. Modern therapeutic alternatives, such as non-vitamin K oral agents (dabigatran, rivaroxaban, apixaban, edoxaban), have appeared. In this study, we aimed to evaluate the role of oral anticoagulant therapy, especially non-vitamin K, in managing patients with both pathologies.